NeuroSense Therapeutics (NRSN) CEO Ben-Noon Buys $200K of Stock
CEO Alon Ben-Noon purchased 250,000 shares of NeuroSense Therapeutics at $0.80 each.
Reviewed by automated data checks against the source filing. How we make and check alerts
Alon Ben-Noon, Chief Executive Officer at NeuroSense Therapeutics Ltd. ($NRSN), bought 250,000 shares at an average price of $0.80, worth about $200,000, on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NRSN is up 9.9% after 1 week, up 0.4% after 1 month and down 78.0% to date (from the $13.98 close on Jun 16, 2026).
NRSN
NeuroSense Therapeutics Ltd.
Key Points
- Alon Ben-Noon, CEO of NeuroSense Therapeutics, bought 250,000 shares on June 16, 2026, at an average price of $0.80 each, totaling $200,000.
- Shares of NasdaqCM:NRSN traded near $0.70 with a 52-week range of $0.63 to $2.52 and a market cap of about $25.5 million.
- Peers like UBS Group AG increased holdings, while Yorkville Advisors Global reduced its stake in NeuroSense.
Get $NRSN trade alerts by text
We text you when insiders, Congress or big funds trade $NRSN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated NeuroSense Therapeutics Ltd. alert may contain errors. Disclosures
Alon Ben-Noon, the Chief Executive Officer of NeuroSense Therapeutics Ltd. (NasdaqCM:NRSN), made a significant insider purchase on June 16, 2026. He acquired 250,000 shares at a price of $0.80 each, amounting to a total investment of $200,000. This transaction was not part of a pre-arranged trading plan.
Insider Buying and Selling at NeuroSense Therapeutics Ltd.
On the same day, Or Eisenberg, the Chief Financial Officer, also bought 250,000 shares at the same price. Earlier in the year, Niva Russek-Blum, the Chief Technology Officer, and Hagit Binder, the General Manager, each purchased 200,000 shares on March 26, 2026.
Other Institutional Activity in NeuroSense Therapeutics
Yorkville Advisors Global, LP reduced its holdings by 22,000 shares, ending with 78,000 shares valued at about $58,890. Independent Advisor Alliance added 50,000 shares, bringing its total to 50,000 shares worth approximately $37,750. UBS Group AG increased its stake by 18,225 shares, now holding 49,096 shares valued at roughly $37,067.
NeuroSense Therapeutics Ltd. Stock Down 88.9%
Shares of NeuroSense Therapeutics traded around $0.70. The company has a market cap of approximately $25.5 million. It has a forward P/E ratio that isn't meaningful due to its lack of profitability and a beta of 1.541. The stock's 52-week range is between $0.63 and $2.52, with a 50-day moving average of $0.78 and a 200-day moving average of $0.95.
Analysts Set New Price Targets
On April 8, 2026, D. Boral Capital maintained a 'buy' rating with a price target of $14. Roth Capital initiated coverage with a 'buy' rating and a $3 target on March 10, 2026. The consensus among analysts is a 'strong buy' with an average target price of $6.50 based on three opinions.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd. is a biotechnology company based in Herzliya, Israel, focusing on treatments for neurodegenerative diseases. Their lead product, PrimeC, is in advanced clinical trials for amyotrophic lateral sclerosis. The company also has preclinical projects targeting Parkinson's and Alzheimer's diseases. Founded in 2017, it operates with a small team of 17 employees under CEO Alon Ben-Noon.
Bottom Line
NeuroSense Therapeutics has seen insider buying activity, with CEO Alon Ben-Noon making a notable purchase. Investors often watch insider transactions for potential signals about a company's future. However, it's important to remember that these filings are retrospective and may not reflect current positions.
Related Filing Alerts
Source: Alon Ben-Noon's Form 4 filing on $NRSN (Jun 16, 2026). Find the original filing: NRSN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts